Kamada (KMDA) Non-Current Assets (2012 - 2026)
Kamada's (KMDA) quarterly Non-Current Assets came in at $183.8 million in Q1 2026, down 1.51% YoY from $186.6 million in Q1 2025, and down 1.0% on a QoQ basis from $185.6 million in Q4 2025.
Kamada (KMDA) Non-Current Assets (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 13 years of Non-Current Assets data on file, last reported at $183.8 million in Q1 2026.
- Quarterly Non-Current Assets fell 1.51% year-over-year to $183.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $738.8 million (down 0.95% YoY) and the FY2025 annual result came in at $185.6 million, down 1.21% from the prior year.
- Non-Current Assets slipped to $183.8 million in Q1 2026, from $185.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $343.0 billion in Q1 2024 to a low of $183.4 million in Q4 2022.
- A 5-year average of $77.6 billion and a median of $185.6 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 850359.94% — and 2025, when it slumped 99.95%.
- Tracing KMDA's Non-Current Assets over 5 years: stood at $183.4 million in 2022, then increased by 0.86% to $184.9 million in 2023, then grew by 1.6% to $187.9 million in 2024, then dropped by 1.21% to $185.6 million in 2025, then fell by 1.0% to $183.8 million in 2026.
- The last three Non-Current Assets figures came in at $183.8 million (Q1 2026), $185.6 million (Q4 2025), and $184.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.96 Bn |
| 10 | Kamada | 458.29 Mn | 428.82 Mn | 22.47 Mn | 183.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 183.59 Mn |
| Mar 31, 2026 | 183.79 Mn |
| Dec 31, 2025 | 185.64 Mn |
| Sep 30, 2025 | 184.48 Mn |
| Jun 30, 2025 | 184.90 Mn |
| Mar 31, 2025 | 186.61 Mn |
| Dec 31, 2024 | 187.91 Mn |
| Sep 30, 2024 | 186.80 Mn |
| Jun 30, 2024 | 184.61 Mn |
| Mar 31, 2024 | 343.02 Bn |
| Dec 31, 2023 | 184.95 Mn |
| Sep 30, 2023 | 336.90 Bn |
| Jun 30, 2023 | 184.71 Mn |
| Mar 31, 2023 | 316.79 Bn |
| Dec 31, 2022 | 183.37 Mn |
| Sep 30, 2022 | 319.64 Bn |
| Jun 30, 2022 | 185.53 Mn |
| Mar 31, 2022 | 186.93 Mn |
| Dec 31, 2021 | 188.62 Mn |
| Sep 30, 2021 | 37.58 Mn |